QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Q32 Bio Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.79+0.27 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $158.47M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
74.6%
22M of 30M shares
Institutional holders
71
27 new, 8 sold out
Net institutional buying
13M
In Q2 2026
Insider trades, 12 months
4 buys · 8 sales
Net bought $29.54M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | 958,768 | 5.70% | 13G (passive) amendment | Mar 31, 2026 |
| Opaleye, L.P. | 931,000 | 5.49% | 13G (passive) amendment | Jun 30, 2026 |
| Acorn Bioventures, L.P. | 803,425 | 6.70% | 13D (active) | Mar 25, 2024 |
| Orbimed Advisors LLC | 4,127,987 | 13.90% | 13D (active) amendment | Jul 16, 2026 |
| Boxer Holdings GP, LLC | 3,149,310 | 13.30% | 13G (passive) | Jun 30, 2026 |
| ADAR1 Capital Management, LLC | 3,120,824 | 5.40% | 13G (passive) | Mar 4, 2024 |
| Bvf Partners L P/Il | 2,367,524 | 9.99% | 13G (passive) | May 28, 2026 |
| Peter Kolchinsky | 2,332,457 | 9.80% | 13G (passive) | May 28, 2026 |
| Orbimed Capital Gp Vii LLC | 2,252,987 | 13.30% | 13D (active) amendment | May 5, 2026 |
| Fhmlsp, L.L.C. | 1,755,116 | 5.90% | 13G (passive) | Oct 2, 2026 |
| Opaleye Management Inc. | 1,256,228 | 8.59% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of QTTB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 4,127,987 | 13.87% | $52.59M | +1,875,000 | 0.97% |
| Boxer Capital Management, LLC | 3,149,310 | 10.58% | $40.12M | New | 3.02% |
| Atlas Venture Life Science Advisors, LLC | 2,717,106 | 9.13% | $34.62M | +625,000 | 3.93% |
| Bvf Inc/Il | 2,350,000 | 7.89% | $29.94M | New | 0.77% |
| Ra Capital Management, L.P. | 2,332,457 | 7.84% | $29.72M | New | 0.26% |
| Point72 Asset Management, L.P. | 1,173,396 | 3.94% | $14.95M | New | 0.02% |
| Opaleye Management Inc. | 931,000 | 3.13% | $11.86M | −325,228 | 1.07% |
| Logos Global Management LP | 800,000 | 2.69% | $10.19M | New | 0.44% |
| SummitTX Capital, L.P. | 733,774 | 2.46% | $9.35M | New | 0.24% |
| Vanguard Capital Management LLC | 518,803 | 1.74% | $6.61M | +212,402 | 0.00% |
| Ikarian Capital, LLC | 430,000 | 1.44% | $5.48M | New | 0.59% |
| Woodline Partners LP | 286,212 | 0.96% | $3.65M | New | 0.01% |
| American Century Companies Inc | 272,752 | 0.92% | $3.47M | +253,982 | 0.00% |
| Sanofi | 244,083 | 0.82% | $3.11M | – | 0.58% |
| Acadian Asset Management LLC | 218,234 | 0.73% | $2.78K | +45,648 | 0.00% |
| Acorn Capital Advisors, LLC | 216,171 | 0.73% | $2.75M | −98,881 | 0.75% |
| Renaissance Technologies LLC | 179,600 | 0.60% | $2.29M | −27,315 | 0.00% |
| Jane Street Group, LLC | 162,747 | 0.55% | $2.07M | +97,148 | 0.00% |
| Monimus Capital Management, LP | 132,036 | 0.44% | $1.68M | −2,274 | 0.39% |
| Boothbay Fund Management, LLC | 130,427 | 0.44% | $1.66M | New | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 71 | 22M | 74.6% | 27 / 18 | 13 / 8 | 15M | 2M |
| Q1 2026 | 53 | 9M | 31.7% | 11 / 14 | 9 / 8 | 2M | 1M |
| Q4 2025 | 52 | 8M | 27.0% | 7 / 9 | 20 / 8 | 0M | 1M |
| Q3 2025 | 53 | 8M | 28.3% | 8 / 10 | 18 / 16 | 0M | 1M |
| Q2 2025 | 61 | 9M | 30.2% | 10 / 12 | 19 / 22 | 0M | 1M |
| Q1 2025 | 73 | 9M | 31.6% | 8 / 17 | 20 / 26 | 0M | 2M |
| Q4 2024 | 92 | 11M | 36.9% | 40 / 22 | 10 / 21 | 4M | 2M |
| Q3 2024 | 73 | 9M | 30.6% | 28 / 18 | 8 / 8 | 2M | 1M |
| Q2 2024 | 54 | 8M | 27.1% | 20 / 16 | 6 / 4 | 1M | 0M |
| Q1 2024 | 38 | 7M | 25.0% | 38 / 0 | 0 / 0 | 7M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of QTTB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 389,115 | 1.31% | $4.96M | 0.00% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 128,510 | 0.43% | $1.42M | 0.01% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 119,269 | 0.40% | $1.52M | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Fund | 34,613 | 0.12% | $440.97K | 0.45% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 30,017 | 0.10% | $331.69K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 29,465 | 0.10% | $375.38K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 16,801 | 0.06% | $185.65K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 15,339 | 0.05% | $169.50K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 14,652 | 0.05% | $229.74K | 0.00% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 8,325 | 0.03% | $91.99K | 0.00% | May 31, 2026 |
| Small-Cap Value Portfolio | 6,223 | 0.02% | $79.28K | 0.02% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 5,934 | 0.02% | $75.60K | 0.00% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 4,890 | 0.02% | $76.68K | 0.00% | Jul 31, 2026 |
| Vanguard Balanced Index Fund | 4,485 | 0.02% | $57.14K | 0.00% | Jun 30, 2026 |
| Column Small Cap Fund | 1,976 | 0.01% | $21.83K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jodie Pope Morrison | CEO, Director | 343,259 | 1.15% | Aug 27, 2026 |
| Lee Kalowski | CFO and President | 138,471 | 0.47% | Aug 27, 2026 |
| Shelia M. Violette | Chief Scientific Officer | 164,048 | 0.55% | Aug 27, 2026 |
| Jason Campagna | Chief Medical Officer | 37,500 | 0.13% | Feb 26, 2025 |
| Mary Thistle | Director | – | – | Jul 21, 2026 |
| David S. Grayzel | Director | 2,092,106 | 7.03% | Jul 21, 2026 |
| Kathleen Laporte | Director | 5,431 | 0.02% | Jul 21, 2026 |
| Diyong Xu | Director, 10% owner | 625,000 | 2.10% | Jul 21, 2026 |
| Mark T. Iwicki | Director | – | – | Jul 21, 2026 |
| Arthur Tzianabos | Director | 7,983 | 0.03% | Jul 21, 2026 |
| Sven Ante Lundberg | Director | 1,200 | 0.00% | Jul 21, 2026 |
| Isaac Manke | Director | 53,521 | 0.18% | Jul 21, 2026 |
| Genesis GP LLC OrbiMed | Director, 10% owner | – | – | Jun 1, 2026 |
| Capital GP VII LLC OrbiMed | Director, 10% owner | 3,502,987 | 11.77% | Jun 1, 2026 |
| Advisors Llc Orbimed | Director, 10% owner | 2,252,987 | 7.57% | Jun 1, 2026 |
| Atlas Venture Associates Opportunity III, L.P. | – | 625,000 | 2.10% | Jun 8, 2026 |
| Atlas Venture Opportunity Fund Ill, L.P. | – | – | – | Jun 8, 2026 |
| Atlas Venture Associates Opportunity III, LLC | – | – | – | Jun 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jodie Pope Morrison CEO, Director | Aug 25, 2026 | Sale | −9,845 | $16.56 | $163.03K | 343,259 |
| Shelia M. Violette Chief Scientific Officer | Aug 25, 2026 | Sale | −2,798 | $16.56 | $46.33K | 127,771 |
| Lee Kalowski CFO and President | Aug 25, 2026 | Sale | −3,972 | $16.56 | $65.78K | 138,471 |
| Lee Kalowski CFO and President | Jul 16, 2026 | Award | +53,250 | – | – | 142,443 |
| Jodie Pope Morrison CEO, Director | Jul 16, 2026 | Award | +132,000 | – | – | 353,104 |
| Shelia M. Violette Chief Scientific Officer | Jul 16, 2026 | Award | +37,500 | – | – | 130,569 |
| Isaac Manke Director | Jun 30, 2026 | Option exercise | +53,521 | $2.80 | $149.86K | 53,521 |
| Capital GP VII LLC OrbiMed Director, 10% owner | May 28, 2026 | Buy | +1,250,000 | $8.00 | $10.00M | 3,502,987 |
| Capital GP VII LLC OrbiMed Director, 10% owner | May 28, 2026 | Buy | +625,000 | $8.00 | $5.00M | 625,000 |
| Diyong Xu Director, 10% owner | May 28, 2026 | Buy | +625,000 | $8.00 | $5.00M | 625,000 |
| Diyong Xu Director, 10% owner | May 28, 2026 | Buy | +1,250,000 | $8.00 | $10.00M | 3,502,987 |
| Jodie Pope Morrison CEO, Director | Feb 25, 2026 | Sale | −9,896 | $4.51 | $44.63K | 89,104 |
| Lee Kalowski CFO and President | Feb 25, 2026 | Sale | −3,995 | $4.51 | $18.02K | 35,943 |
| Shelia M. Violette Chief Scientific Officer | Feb 25, 2026 | Sale | −2,815 | $4.51 | $12.70K | 55,569 |
| Jodie Pope Morrison CEO, Director | Feb 24, 2026 | Award | +132,000 | – | – | 221,104 |
| Lee Kalowski CFO and President | Feb 24, 2026 | Award | +53,250 | – | – | 89,193 |
| Shelia M. Violette Chief Scientific Officer | Feb 24, 2026 | Award | +37,500 | – | – | 93,069 |
| Jodie Pope Morrison CEO, Director | Dec 2, 2025 | Sale | −22,506 | $3.46 | $77.87K | 99,000 |
| Lee Kalowski CFO and President | Dec 2, 2025 | Sale | −9,072 | $3.46 | $31.39K | 39,938 |
| Shelia M. Violette Chief Scientific Officer | Aug 26, 2025 | Sale | −2,990 | $1.80 | $5.38K | 58,384 |
| Lee Kalowski CFO and President | Aug 26, 2025 | Sale | −4,240 | $1.80 | $7.63K | 49,010 |
| Jodie Pope Morrison CEO, Director | Aug 26, 2025 | Sale | −10,494 | $1.80 | $18.89K | 121,506 |
| Lee Kalowski CFO and President | Feb 24, 2025 | Award | +53,250 | – | – | 53,250 |
| Jason Campagna Chief Medical Officer | Feb 24, 2025 | Award | +37,500 | – | – | 37,500 |
| Jodie Pope Morrison CEO, Director | Feb 24, 2025 | Award | +132,000 | – | – | 132,000 |
| Shelia M. Violette Chief Scientific Officer | Feb 24, 2025 | Award | +37,500 | – | – | 61,374 |
| Shelia M. Violette Chief Scientific Officer | Oct 15, 2024 | Option exercise | +6,000 | $7.29 | $43.74K | 23,874 |
| Shelia M. Violette Chief Scientific Officer | Oct 11, 2024 | Option exercise | +4,574 | $3.12 | $14.27K | 17,874 |
| Shelia M. Violette Chief Scientific Officer | Oct 8, 2024 | Option exercise | +13,300 | $3.12 | $41.50K | 13,300 |
| Arthur Tzianabos Director | Mar 25, 2024 | Sale | −265 | $24.20 | $6.41K | 7,983 |
| Arthur Tzianabos Director | Mar 25, 2024 | Option exercise | +1,095 | – | – | 8,248 |
| Paul Alloway See Remarks | Mar 25, 2024 | Sale(10b5-1 plan) | −268 | $24.21 | $6.49K | 2,596 |
| Charles Michaud Jr See Remarks | Mar 25, 2024 | Sale(10b5-1 plan) | −75 | $24.20 | $1.82K | 927 |
| Charles Michaud Jr See Remarks | Mar 25, 2024 | Option exercise | +6,448 | – | – | 18,046 |
| Paul Alloway See Remarks | Mar 25, 2024 | Option exercise | +23,530 | – | – | 51,566 |
| Arthur Tzianabos Director | Jan 9, 2024 | Sale(10b5-1 plan) | −13,037 | $0.57 | $7.43K | 128,778 |
| Paul Alloway See Remarks | Jan 3, 2024 | Sale(10b5-1 plan) | −7,280 | $0.57 | $4.15K | 28,036 |
| Charles Michaud Jr See Remarks | Jan 3, 2024 | Sale(10b5-1 plan) | −1,708 | $0.57 | $974 | 11,598 |
| Arthur Tzianabos Director | Jan 1, 2024 | Option exercise | +14,280 | – | – | 122,675 |
| Arthur Tzianabos Director | Jan 1, 2024 | Option exercise | +19,140 | – | – | 141,815 |
| Charles Michaud Jr See Remarks | Jan 1, 2024 | Option exercise | +1,056 | – | – | 10,666 |
| Charles Michaud Jr See Remarks | Jan 1, 2024 | Option exercise | +2,640 | – | – | 13,306 |
| Charles Michaud Jr See Remarks | Jan 1, 2024 | Option exercise | +544 | – | – | 9,610 |
| Paul Alloway See Remarks | Jan 1, 2024 | Option exercise | +8,910 | – | – | 35,316 |
| Paul Alloway See Remarks | Jan 1, 2024 | Option exercise | +4,420 | – | – | 21,126 |
| Paul Alloway See Remarks | Jan 1, 2024 | Option exercise | +5,280 | – | – | 26,406 |
| Albert Seymour See Remarks, Director | Sep 6, 2023 | Sale(10b5-1 plan) | −1,448 | $1.15 | $1.67K | 150,874 |
| Albert Seymour See Remarks, Director | Sep 6, 2023 | Option exercise | +4,620 | – | – | 152,322 |
| Julie Jordan Chief Medical Officer | Aug 3, 2023 | Sale(10b5-1 plan) | −109 | $1.39 | $152 | 4,160 |
| Julie Jordan Chief Medical Officer | Aug 3, 2023 | Option exercise | +387 | – | – | 4,269 |
| Julie Jordan Chief Medical Officer | Aug 3, 2023 | Sale(10b5-1 plan) | −1,308 | $1.39 | $1.82K | 7,496 |
| Julie Jordan Chief Medical Officer | Aug 3, 2023 | Option exercise | +1,548 | – | – | 4,318 |
| Julie Jordan Chief Medical Officer | Aug 3, 2023 | Sale(10b5-1 plan) | −436 | $1.39 | $606 | 3,882 |
| Julie Jordan Chief Medical Officer | Aug 3, 2023 | Option exercise | +4,644 | – | – | 8,804 |
| Julie Jordan Chief Medical Officer | Aug 2, 2023 | Option exercise | +350 | – | – | 2,869 |
| Julie Jordan Chief Medical Officer | Aug 2, 2023 | Sale(10b5-1 plan) | −99 | $1.31 | $130 | 2,770 |
| Paul Alloway See Remarks | Mar 2, 2023 | Sale(10b5-1 plan) | −10,965 | $1.45 | $15.90K | 16,706 |
| W. Bradford Smith See Remarks | Jan 9, 2023 | Sale(10b5-1 plan) | −3,729 | $1.39 | $5.18K | 14,219 |
| Paul Alloway See Remarks | Jan 9, 2023 | Sale(10b5-1 plan) | −3,090 | $1.39 | $4.30K | 20,103 |
| Arthur Tzianabos Director | Jan 9, 2023 | Sale(10b5-1 plan) | −10,616 | $1.39 | $14.76K | 108,395 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kalowski Lee Officer | Dec 2, 2025 | 9,072 | $31.40K | Dec 2, 2025 | Restricted Stock |
| Morrison Jodie Officer, Director | Dec 2, 2025 | 22,506 | $77.87K | Dec 2, 2025 | Restricted Stock |